Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 11.38 GBp
Change Today -0.375 / -3.19%
Volume 219.6K
OXP On Other Exchanges
Symbol
Exchange
London
OTC US
As of 11:35 AM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

oxford pharmascience group p (OXP) Snapshot

Open
11.75 GBp
Previous Close
11.75 GBp
Day High
11.75 GBp
Day Low
11.38 GBp
52 Week High
06/22/15 - 13.50 GBp
52 Week Low
12/10/14 - 3.23 GBp
Market Cap
137.1M
Average Volume 10 Days
789.0K
EPS TTM
-0.0028 GBp
Shares Outstanding
1.2B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXFORD PHARMASCIENCE GROUP P (OXP)

Related News

No related news articles were found.

oxford pharmascience group p (OXP) Related Businessweek News

No Related Businessweek News Found

oxford pharmascience group p (OXP) Details

Oxford Pharmascience Group Plc, a specialty pharmaceutical company, re-develops medicines using proprietary technology platforms in the United Kingdom, Brazil, the Middle East, the Far East, and internationally. The company’s product pipeline includes programs in non-steroidal anti-inflammatory drugs comprising Ibuprofen, Naproxen, Diclofenac, and Aspirin, as well as statins, such as Atorvastatin for pain relief and cardiovascular disease indications. It also provides calcium/vitamin D chews that taste better and dissolve faster. The company was formerly known as Oxford Nutrascience Group Plc and changed its name to Oxford Pharmascience Group Plc in May 2011. Oxford Pharmascience Group Plc was founded in 2008 and is based in London, the United Kingdom.

Founded in 2008

oxford pharmascience group p (OXP) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: 150.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 8.0K GBP
Compensation as of Fiscal Year 2013.

oxford pharmascience group p (OXP) Key Developments

Oxford Pharmascience Group plc Announces Initiation of Pilot Clinical Study for Naproxen

Oxford Pharmascience Group Plc announced the initiation of dosing in its pilot clinical study of 25 0mg OXPzero Naproxen (OXP005). OXP005 uses Oxford Pharmascience's patented OXPzero technology in an immediate release oral formulation and aims to provide a significantly reduced gastrointestinal (GI) side effect profile compared to standard naproxen tablets. Following on from the recent announcement of the successful proof-of-concept pharmacokinetic study, the Company announced that it has progressed to an endoscopic evaluation study to prove the reduced GI irritation of OXP005. The purpose of this Phase I, randomised, controlled pilot study is to assess the severity of upper GI damage via endoscopic assessment following 7 days treatment of 1 g/day naproxen dosed as either OXP005 or Naprosyn. Headline results are expected to be released in late second quarter or early third quarter 2015. Naproxen currently has worldwide sales of $1 billion and is one of the most important molecules in the NSAID category due to a number of factors: its pain relief and anti-inflammatory effect are longer lasting than other NSAID molecules allowing for less frequent dosing regimes, which aids patient compliance; and its use is also associated with a lower incidence of cardiovascular complications compared to all other NSAIDs3. It is therefore the preferred NSAID for long-term use in people with a high risk of cardiovascular complications. However, the widespread use of Naproxen is hampered by the higher risk of GI irritation relative to Ibuprofen3. Accordingly, if GI irritation is reduced, OXP005 could provide a highly appealing combination of long lasting pain relief, lower cardiovascular risk profile and reduced GI irritation.

Oxford Pharmascience Group Plc Unveils Positive Results from OXP005 Comparative Study

Oxford Pharmascience Group Plc announced the pilot study comparing its OXPzero Naproxen (OXP005) anti-inflammatory treatment with standard US and EU drug naproxen (Naprosyn) had delivered positive results. The comparative pharmacokinetic (PK) study showed OXP005 to have an immediate release profile and bioequivalence to naproxen based on mean values. OXP005 delivers 250mg of reduced gastric irritation naproxen as a result of Oxford Pharmascience's  patent-protected OXPzero technology. In light of the pilot study results, Oxford Pharmascience is moving ahead with a proof of concept endoscopy study that will compare the extent of gastroduodenal irritation for OXP005 and Naprosyn. The necessary approvals for this study have been obtained and potential subjects identified so dosing is expected to start at any moment.

Oxford Pharmascience Announces Pilot Comparative Pharmacokinetics Study of OXPzero™ Naproxen

Oxford Pharmascience announced that the pilot comparative pharmacokinetics study of OXPzero™ Naproxen, which commenced on 5 March, has been successful and the headline data from the trial demonstrates bioequivalence of OXP005 to Naprosyn® (generic naproxen). OXPzero™ Naproxen aims to deliver 250mg of reduced gastric irritation naproxen via the Company's patent protected OXPzero™ technology in an immediate release oral formulation in order to provide a significantly reduced gastrointestinal (GI) side effect profile compared to standard naproxen tablets. The headline PK data showed results which demonstrate bioequivalence and that the OXPzero™technology has been successfully optimised to enable immediate and complete drug release. Full results of the study will be published in the following weeks. Based on this data, the company will now progress to a proof of concept endoscopy study to demonstrate the reduced GI irritation benefit of OXPzero™ Naproxen, as was previously demonstrated for OXPzero™ Ibuprofen in an earlier formulation. Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used classes of drugs, with combined annual sales in excess of $12 billion and more than 30 million users worldwide consuming NSAIDs each day (source: Evaluate Pharma). Chronic use of NSAIDs causes well-documented GI side effects, including ulcers and bleeding, and leads to significant morbidity and mortality in a substantial number of patients, with significant associated healthcare costs. The OXPzero™ platform technology reduces these risks and is being selectively applied to the most commonly used NSAID molecules, namely ibuprofen, naproxen, diclofenac and aspirin.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXP:LN 11.38 GBp -0.375

OXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXP.
View Industry Companies
 

Industry Analysis

OXP

Industry Average

Valuation OXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 168.2x
Price/Book 16.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 201.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD PHARMASCIENCE GROUP P, please visit www.oxfordpharmascience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.